Somatostatin infusion withdrawal: Studies in the acute and recovery phase of anorexia nervosa, and in obesity

European Journal of Endocrinology

Volumn 148, Issue 2, 2003, Pages 237-243

  Pincelli, Angela I ^c   Rigamonti, Antonello E ^a   Scacchi, Massimo ^c   Cella, Silvano G ^a   Cappa, Marco ^b   Cavagnini, Francesco ^c   Müller, Eugenio E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GONADORELIN; GROWTH HORMONE; INSULIN; LIOTHYRONINE; SERMORELIN; SOMATOMEDIN C; SOMATOSTATIN; THYROTROPIN;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG INFUSION; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FREE LIOTHYRONINE INDEX; GONADORELIN RELEASE; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MORBID OBESITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THYROTROPIN BLOOD LEVEL;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; OBESITY, MORBID; OSMOLAR CONCENTRATION; REFERENCE VALUES; SOMATOSTATIN;

EID: 0037295401     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480237     Document Type: Article

References (66)

1. Alvarez LC, Diams CD, Castro A, Rossman LG, Vanderlaan EF & Vanderlaan WP. Growth hormone in malnutrition. Journal of Clinical Endocrinology 1972 34 400-409.
2. Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. Journal of Clinical Endocrinology and Metabolism 1981 53 1247-1250.
3. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. Journal of Clinical Investigation 1988 81 968-975.
4. Asplin CM, Faria CS, Carlsen EC, Vaccaro VA, Barr RE, Iranmanesh A et al. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1989 69 239-245.
5. Dieguez C, Page MD & Scanlon MF. Growth hormone neuroregulation and its alterations in disease states. Clinical Endocrinology 1989 28 109-121.
6. Scacchi M, Pincelli AI, Caumo A, Tomasi P, Delitala G, Baldi G et al. Spontaneous nocturnal growth hormone secretion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1997 82 3225-3229.
7. Tamai HT, Komaki G, Matsubayashi S, Kobayashi N, Mori K, Nakagawa T et al. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced-GH secretion in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1990 70 738-741.
8. Rolla M, Andreoni A, Belliti D, Cristofani R, Federghini M & Müller EE. Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia and atypical eating disorders. Biological Psychiatry 1991 29 1079-1091.
9. Counts DR, Gwirtsman H, Carlsson LMS, Lesem M & Cutler GB Jr. The effects of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. Journal of Clinical Endocrinology and Metabolism 1992 75 762-767.
10. Cuneo RC, Hickman PE, Wallace JD, Teh BT, Ward G, Veldhuis JD et al. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clinical Endocrinology 1995 43 265-275.
11. Jenkins RC & Ross RJM. The endocrinology of the critically ill. Current Opinion in Endocrinology and Diabetes 1996 3 138-145.
12. Van den Berghe VG, De Zegher F, Lauwers P & Vedlhuis JD. Growth hormone secretion in critical illness: effect of dopamine. Journal of Clinical Endocrinology and Metabolism 1994 79 1141-1146.
13. Ross RJM & Chew SL. Acquired growth hormone resistance. European Journal of Endocrinology 1995 132 655-660.
14. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu LO & Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effect on both hypothalamus and the pituitary Science 1981 212 1279-1281.
15. Ceda GP, Davis RG & Hoffman AR. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology 1987 120 1658-1662.
16. Thissen JP, Ketelslegers GM & Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrinological Reviews 1994 15 80-101.
17. Frankel RJ & Jenkins JS. Hypothalamic pituitary function in anorexia. nervosa. Acta Endocrinologica 1975 78 209-221.
18. Brambilla F, Bellodi L, Arancio C, Ronchi P & Limonta D. Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 2001 26 393-409.
19. De Marinis L, Folli G, D'Amico C, Mancini A, Sambo P, Tofani A et al. Differential effect of feeding on the ultradian variation of the growth hormone (GH) response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1988 66 598-602.
20. Brambilla F, Ferrari E, Cavagnini F, Invitti C, Zanoboni A, Massironi R et al. Alpha 2-adrenoceptor sensitivity in anorexia nervosa: GH response to clonidine or GHRH stimulation. Biological Psychiatry 1989 25 256-264.
21. Casper RC, Pandey G, Jaspan JB & Rubenstein AH. Eating attitudes and glucose tolerance in anorexia nervosa patients at 8 years follow-up compared to control subjects. Psychiatry Research 1988 25 283-299.
22. Rolla M, Andreoni A, Belliti D, Ferdeghini M & Ferrannini E. Failure of glucose infusion to suppress the exaggerated GH response to GHRH in patients with anorexia nervosa. Biological Psychiatry 1990 27 215-222.
23. Maeda K, Kato Y, Yamaguchi N, Chihara K & Ohgo S. Growth hormone release following thyrotropin-releasing hormone injection into patients with anorexia nervosa. Acta Endocrinologica 1976 81 1-8.
24. Maeda K, Tanimoto K & Chihara K. Abnormal growth hormone release following luteinizing hormone releasing hormone in anorexia nervosa. Japanese Journal of Psychiatric Neurology 1987 41 41-45.
25. Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S et al. Arginine but nor pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biological Psychiatry 1994 36 689-695.
26. Gianotti L, Arvat E, Valetto MR, Ramunni J, Di Vito L, Maccagno B et al. Effects of beta-adrenergic agonists and antagonists on the GH response to GHRH in anorexia nervosa. Biological Psychiatry 1998 43 181-187.
27. Scacchi M, Invitti C, Pincelli AI, Pandolfi C, Dubini A & Cavagnini F. Lack of growth hormone response to acute administration of dexamethasone in anorexia nervosa. European Journal of Endocrinology 1995 132 152-158.
28. Müller EE, Locatelli V & Cocchi D. Neuroendocrine control of growth hormone secretion. Physiological Reviews 1999 79 511-607.
29. Gerner RH & Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Research 1982 238 298-302.
30. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML & Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. Journal of Clinical Endocrinology and Metabolism 1991 72 51-59.
31. Scacchi M, Pincelli AI & Cavagnini F. Growth hormone in obesity. International Journal of Obesity and Related Metabolic Disorders 1999 23 260-271.
32. Maccario M, Grottoli S, Procopio M, Oleandri SE, Rossetto R, Gauna C et al. The GH/IGF-I axis in obesity: influence of neuroendocrine and metabolic factors. International Journal of Obesity and Related Metabolic Disorders 2000 24 (Suppl 2) S96-S99.
33. Kopelman PG, Noonan K, Goulton R & Forrest AJ. Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity. Clinical Endocrinology 1985 23 87-94.
34. Micic D, Macut D, Popovic V, Kendereski A, Sumarac-Dumano-vicacute M, Zoricacute S et al. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Metabolism 1999 48 525-530.
35. Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S et al. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. Minerva Endocrinologica 1999 24 107-111.
36. Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F et al. In obesity the somatotrope response to GHRH or arginine is inhibited by somatostatin or pirenzepine but not by oral glucose load. Journal of Clinical Endocrinology and Metabolism 1995 80 3774-3778.
37. Miki N, Ono M & Shizume K. Withdrawal of endogenous somatostatin induces secretion of growth hormone-releasing factor in rats. Journal of Endocrinology 1988 117 245-252.
38. Cella SG, Luceri M, Cattaneo L, Torsello A & Müller EE. Somatostatin withdrawal as generator of pulsatile GH release in the dog: a possible tool to evaluate the endogenous GHRH tone? Neuroendocrinology 1996 63 481-488.
39. Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG et al. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide. European Journal of Endocrinology 2001 145 635-644.
40. Hindmarsh PC, Brain CE, Robinson IC, Matthews DR & Brook CG. The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man. Clinical Endocrinology 1991 35 353-360.
41. degli Uberti EC, Ambrosio MR, Cella SG, Margutti AR, Trasforini G, Rigamonti AE et al. Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man. Journal of Clinical Endocrinology and Metabolism 1997 82 2885-2888.
42. Cappa M, Rigamonti AE, Bizzarri C, Porzio O, Civolani P, Cella SG et al. Somatostatin infusion withdrawal: studies in normal children and in children with growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1999 84 4426-4430.
43. Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C & Cordido F. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity. Clinical Endocrinology 2002 56 487-492.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders IV-TR. Washington, DC: American Psychiatric Press, 2000.
45. Gianotti L, Broglio F, Ramunni J, Lanfranco F, Gauna C, Benso A et al. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness. Eating and Weight Disorders 1998 3 64-70.
46. Kelijman M & Frohman LA. Enhanced growth hormone (GH) responsiveness to growth hormone-releasing hormone after dietary manipulation in obese and non obese subjects. Journal of Clinical Endocrinology and Metabolism 1988 66 489-495.
47. Salerno F, Locatelli V & Müller EE. Growth hormone hyperresponsiveness to growth hormone releasing hormone in patients with severe liver disease. Clinical Endocrinology 1987 27 183-187.
48. Plotsky PM & Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science 1985 230 461-463.
49. Robinson IC, Jeffery S & Clark RG. Somatostatin and its physiological significance in regulating the episodic secretion of growth hormone in the rat. Acta Paediatrica Scandinavica 1990 367 (Suppl) 87-92.
50. Stoving RK, Veldhuis JD, Flyvbjerg A, Vinten J, Hangaard J, Koldkjaer OG et al. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. Journal of Clinical Endocrinology and Metabolism 1999 84 2056-2063.
51. Gianotti L, Rolla M, Arvat E, Belliti D, Valetto MR, Ferdeghini M et al. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. Biological Psychiatry 1999 45 334-339.
52. Cordido F, Dieguez C & Casanueva FF. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. Journal of Clinical Endocrinology and Metabolism 1990 70 1361-1370.
53. Loche S, Pintus S, Cella SG, Boghen M, Vannelli S, Benso L et al. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children. Clinical Endocrinology 1990 33 187-192.
54. Lee EJ, Kim KR, Lee KM, Lim SK, Lee HC, Lee JH et al. Reduced growth hormone response to L-dopa and pyridostigmine in obesity. International Journal of Obesity and Related Metabolic Disorders 1994 18 465-468.
55. Muruais C, Cordido F, Morales MJ, Casanueva FF & Dieguez C. Corticosteroid-induced growth hormone secretion in normal and obese subjects. Clinical Endocrinology 1991 35 485-490.
56. Loche S, Pintus S, Carta D, Muntoni AC, Congiu G, Civolani P et al. The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children. Acta Endocrinologica 1992 126 124-127.
57. Brunani A, Invitti C, Dubini A, Piccoletti R, Bendinelli P, Maroni P et al. Cerebrospinal fluid and plasma concentrations of SRIH, beta-endorphin, CRH, NPY and GHRH in obese and normal weight subjects. International Journal of Obesity and Related Metabolic Disorders 1995 19 17-21.
58. Ahmad I, Finkelstein JA, Downs TR & Frohman LA. Obesity-associated decrease in growth hormone-releasing hormone gene expression: a mechanism for reduced growth hormone mRNA levels in genetically obese Zucker rats. Neuroendocrinology 1993 58 332-337.
59. Ghigo E, Procopio M, Maccario M, Bellone J, Arvat E, Campana S et al. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Hormone and Metabolic Research 1993 25 305-308.
60. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. Journal of Clinical Endocrinology and Metabolism 2001 86 1464-1469.
61. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. Journal of Clinical Endocrinology and Metabolism 2001 86 4753-4758.
62. Lee HM, Wang G, Englander EW, Kojima M & Greeley GH Jr. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002 143 185-190.
63. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E & Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001 50 707-709.
64. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. European Journal of Endocrinology 2001 145 669-673.
65. Wang G, Lee HM, Englander E & Greeley GH. Ghrelin - not just another stomach hormone. Regulatory Peptides 2002 105 75-81.
66. Rigamonti AE, Bonomo SM, Cella SG & Müller EE. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide. Journal of Endocrinology 2002 174 387-394.